Samsung Bioepis Heads For Spin Out To Unlock ‘Hidden Value’
Parent Company Samsung Biologics To Create New Holding Company, Samsung Epis Holdings
Samsung Biologics will retain solely its significant CDMO business, eliminating a perceived conflict of interest, as it pursues an equity spin-off for its biosimilars business Samsung Bioepis.
